Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969852 | 0.79 | POLQ (0.33) | POLQMAPTTP53ALDH1A1POLB | |
| SCHEMBL7978950 | 0.73 | POLQ (0.47) | POLQMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19425667 | 0.70 | LMNA (0.61) | MAPTTP53ALDH1A1LMNAPOLB | |
| SCHEMBL7348767 | 0.70 | HDAC1 (0.50) | POLQMAPTALDH1A1LMNAPOLB | |
| SCHEMBL18689406 | 0.67 | SLC1A3 (0.54) | MAPTTP53ALDH1A1LMNAPOLB | |
| SCHEMBL4163668 | 0.64 | POLQ (0.41) | POLQMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7978872 | 0.63 | HTT (0.40) | TP53RAB9AALDH1A1NPC1LMNA | |
| SCHEMBL18688794 | 0.62 | MAPT (0.50) | MAPTTP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7982394 | 0.62 | PTGIR (0.46) | MAPTTP53RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3242088 | 0.61 | POLQ (0.44) | POLQALDH1A1TLR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353156-B1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| WO-2017053706-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | TEAD1, TEAD2, TEAD3 | POLQ 1641/4885MAPT 1926/4885TP53 536/4885 |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | TEAD1, TEAD2, TEAD3 | POLQ 1641/4885MAPT 1926/4885TP53 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.